ArticleBMC cardiovascular disorders2025
Impact of epicardial adipose tissue volume and hypertension on left ventricular hypertrophy in preclinical heart failure patients with metabolic syndrome.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLeft ventricular hypertrophy (LVH) is a critical risk factor for cardiovascular diseases, yet the interplay between metabolic disorders and hypertension in its pathogenesis remains underexplored.
methodsThis retrospective study investigated the independent and synergistic roles of epicardial adipose tissue (EAT) volume and hypertension in driving LVH among 253 preclinical heart failure patients with metabolic syndrome (MetS). EAT volume was measured via non-contrast computed tomography (CT). Analysis of covariance (ANCOVA) was employed to assess the contributions of metabolic factors and hypertension to LVH. Mediation analysis was conducted to evaluate whether the effect of EAT on LVH is mediated through blood pressure.
resultsPatients with LVH (median age 33 years) exhibited significantly higher prevalence of hypertension (70.9% vs. 36.5%, P < 0.001) and elevated metabolic indices, including fasting glucose, TyG index, and EAT volume (126 vs. 112 cm³, P = 0.005), compared to non-LVH counterparts. Covariance analysis revealed hypertension accounted for 13.5% of LV mass variance, while EAT volume independently contributed 16.5%. Notably, metabolic factors of Mets-IR, uric acid, and body fat mass further modulated hypertension-associated LV remodeling. Mediation analysis demonstrated systolic and diastolic blood pressure partially mediated the EAT-LV mass relationship (mediation effect: 13.2% and 9%, respectively).
conclusionThese findings underscore EAT volume as a strong mediator of metabolic-driven cardiac hypertrophy in preclinical heart failure patients with MetS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.